

Pyrrolizidine Alkaloids from *Lithospermum canescens* Lehm.

Helmut Wiedenfeld^{a*}, Agnieszka Pietrosiuk^b, Mirosława Furmanowa^b, and Erhard Roeder^a

^a Pharmazeutisches Institut der Universität, An der Immenburg 4, D-53121 Bonn, F. R. G.
Fax: +49-2287360317. E-mail: wiedenfeld@uni-bonn.de

^b Department of Biology and Pharmaceutical Botany, Medical University of Warsaw,
Banacha Str. 1, 02-097 Warsaw, Poland

* Author for correspondence and reprint requests

Z. Naturforsch. **58c**, 173–176 (2003); received October 15/November 12, 2002

Seven pyrrolizidine alkaloids (PAs) have been isolated from *Lithospermum canescens* and their structures determined by spectroscopical methods. Besides the known lycopsamine, *O*⁷-acetyl-lycopsamine and *O*⁷-acetylintermediate four new PAs were found. Their structures are *O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(+)-trachelanthoyl-heliotridine (= *O*⁷-(3-hydroxy-3-methyl-butanoyl)-rinderine = canescine), *O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(-)-viridifloryl-heliotridine (= *O*⁷-(3-hydroxy-3-methyl-butanoyl)-echinatine = canescenine) and their *O*¹³-acetyl-derivatives (= acetylcanescine; acetylcanescenine).

Key words: *Lithospermum canescens*, Pyrrolizidine Alkaloids, Canescine and Derivatives

Introduction

Lithospermum canescens Lehm., Boraginaceae (native American name: “hoary puccoon”) grows in open prairies in northern USA and southern Canada. Because it contains pigments of the shikonin-type (Wiedenfeld *et al.*, 1998) it is used as a body dye by native people (Densmore, 1928).

As *L. canescens* belongs to the Boraginaceae family the presence of pyrrolizidine alkaloids (PAs) could be expected.

Based on structural aspects (double-bond in position 1,2; esterification at both necic OH-functions) PAs can show toxic effects. Toxicity occurs not only after oral administration but also after percutaneous absorption although to a smaller extent than by ingestion (Brauchli *et al.*, 1982). Thus, according to the German Federal Health Bureau regulations the sale of PA containing products for external use is restricted in Germany to a daily dose of 100 µg and a maximum use of six weeks per year (Bekanntmachung, 1992). Aerial parts of *L. canescens* were therefore investigated. Seven PAs were isolated and their structures determined by GC-mass spectroscopy and homo- as well as heteronuclear 2D-NMR correlated spectroscopy. Four of them have not been described previously. The known alkaloids belong to the retronecine-type and are *O*⁹-(-)-viridifloryl-retronecine (= lycopsamine), its *O*⁷-acetyl-derivative (= acetyllycopsamine)

and *O*⁷-acetyl-*O*⁹-(+)-trachelanthoyl-retronecine (= acetylintermediate), The new PA show the structures of *O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(+)-trachelanthoyl-heliotridine (= *O*⁷-(3-hydroxy-3-methyl-butanoyl)-rinderine), *O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(-)-viridifloryl-heliotridine (= *O*⁷-(3-hydroxy-3-methyl-butanoyl)-echinatine), *O*¹³-acetyl-*O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(+)-trachelanthoyl-heliotridine, *O*¹³-acetyl-*O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(-)-viridifloryl-heliotridine.

Based on structure-toxicity relationships (Wiedenfeld and Roeder, 1984) toxic side effects must be expected for all substances found.

Results and Discussion

Aerial parts of *L. canescens* were extracted as previously described (Roeder and Wiedenfeld, 1977; Wiedenfeld and Roeder, 1979). From the crude alkaloidal extract **1–7** were isolated (Fig. 1).

The GC-MS spectrum of **1** shows the [M]⁺-peak at 299 indicating the formula C₁₅H₂₅NO₅. Those of **2** and **3** show [M]⁺-Peaks at 341 corresponding to the formulas C₁₇H₂₇NO₆. The further MS fragmentation and also the NMR data of **1–3** are as described earlier (Wiedenfeld and Roeder, 1991; Roeder *et al.*, 1982; Kelley and Seiber, 1992; Roitman, 1983).

The [M]⁺-Peak in the GC-MS spectrum of **4** and **6** occurs at 399 indicating the molecular formulas




Fig. 1: Structures of the isolated Pas: Lycopsamine (**1**), O⁷-acetyl-lycopsamine (**2**), O⁷-acetylintermediate (**3**), O⁷-(3-hydroxy-3-methyl-butanoyl)-O⁹-(+)-trachelanthoyl-heliotridine = canescine (**4**), O⁷-(3-hydroxy-3-methyl-butanoyl)-O⁹-(-)-viridifloryl-heliotridine = canescenine (**5**), O⁷-acetylcanescine (**6**), O⁷-acetylcanescenine (**7**).

C₂₀H₃₃NO₇. Loss of CH₃ leads to *m/z* 384. The ions *m/z* 355 and 338 result from [M]⁺-C₂H₄O and further loss of OH. The cleavage of the ester function at O-9 leads to *m/z* 256 and *m/z* 238. The decay of the O⁷-acid is demonstrated by an ion at *m/z* 220 (loss of OH at C-21), *m/z* 180 (loss of C₃H₇O) and cleavage of the ester function to *m/z* 136. The fragments *m/z* 136, 120, 93 and 80 are typical for retronecine or its isomer heliotridine. The ms spectra of **5** and **7** show the [M]⁺-Peaks at 441 corresponding to the formulas C₂₂H₃₅NO₈. After loss of an acetyl function (indicated by *m/z* 441–426–398) the further fragmentations are similar to those of **4** and **6**; they differ only in intensities.

The ¹H- and ¹³C-NMR-data of **4–7** are summarized in the Experimental part. The assignment was performed by interpretation of H,H- and C,H-correlated spectra. Important structural information is provided by the ¹³C chemical shifts of C-6 (~ 34 ppm), C-7 (~ 74 ppm) and C-8 (~ 75 ppm)

(Jones *et al.*, 1982; Mohanraj and Herz, 1982; Wiedenfeld and Roeder, 1991). These signals establish **4–7** as diesters of heliotridine. This is further confirmed by the ¹H and ¹³C shift for C-9: ~ 4,7/62 ppm as well as by the ¹H data for C-7: ~ 5.4 ppm. The esterifying acid at O-7 is identical for all 4 PA and is characterised by the values for the methylene group C-20 (2.5 and 47 ppm), C-21 (69 ppm) and the methyl groups 22/23 (1.3 and ~ 29 ppm). These data proof the structure of a 3-hydroxy-3-methyl-butanoyl ester. The NMR data for the O-9 acid in **6** are the same as in **1** leading to the structure of a (-)-viridiflorylester. **4** shows differences in the data for H-13 (4.07 instead of 3.89 ppm) and for C-16 and C-17 (17.8 and 14.2 instead of 17.2 and 17.1 ppm). The stereochemistry at C-12 can be deduced by interpretation of the shift difference of the C-9H₂ AB-system (Mohanraj and Herz, 1982; Wiedenfeld and Roeder, 1991). For this aspect values from 0–0.2 ppm indicate an

S-configuration while higher values indicate *R*-configuration. The configuration at C-13 is shown by the H-13 and C-13 data as well as by the shift differences of the C-NMR data for the methyl groups C-16/C-17 (Wiedenfeld and Roeder, 1991). Thus, the values for C-13 (4.07 and 69.5 ppm instead of 3.89 and 71.1 ppm) and C-16/C-17 ($\Delta\text{Hz} = 3.6$ instead of 0.1 ppm) give evidence for a C-12*S* and a 13*R* configuration (= (+)-trachelanthic acid). The data for **5** and **7** differ from those in **4** and **6** only in a downfield shifting of H-13 and C-13 (~ 5.2 and ~ 74 ppm) and the additional data for an acetyl group (~ 2.0 and ~ 21 ppm for CH₃ and 170 ppm for C = O) which confirm the structures as O-13-acetyl-(+)-trachelanthic and a O-13-acetyl(-)-viridifloric acid, respectively. These data proof the structures of *O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(+)-trachelanthoyl-heliotridine (= *O*⁷-(3-hydroxy-3-methyl-butanoyl)-rinderine) (**4**), *O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(-)-viridifloryl-heliotridine (= *O*⁷-(3-hydroxy-3-methyl-butanoyl)-echinatine) (**6**), *O*¹³-acetyl-*O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(+)-trachelanthoyl-heliotridine (**5**), *O*¹³-acetyl-*O*⁷-(3-hydroxy-3-methyl-butanoyl)-*O*⁹-(-)-viridifloryl-heliotridine (**7**).

For the new PAs we propose the names canescine (**4**), canescenine (**6**), acetylcanescine (**5**) and acetylcanescenine (**7**).

All isolated PAs are expected to produce toxic side effects. The PA content (GC) was about 0.02% (dry weight). Therefore, based on the German regulations for external use of preparations from PAs containing plants, application of more than 0.5 g dried plant material per day may expose the user to a health risk.

Experimental

General

NMR-spectra (Bruker AC 400) were measured in CDCl₃/D₆-DMSO at 400 and 100 MHz, respectively. GC-MS: GC: 150° (5 min.) – 250 °C, 10°/min; HP-1, 25 m × 0.32 mm; Inj.: 250 °C, det.: 280 °C; R_t: **1**: 12.67 min, **2**: 13.49 min, **3**: 13.88 min, **4**: 16.79 min, **5**: 17.51 min, **6**: 16.92 min, **7**: 18.14 min; MS: 220 °C; interface: 250 °C; 2000 emV.

Plant material

Plants were collected in July 2000 at Parkland Bot, Togo, Saskatchewan, Canada. A voucher specimen is deposited at the Department of Biology and Pharmaceutical Botany, Medical University of Warsaw, Poland.

Extraction and isolation

Extn. of plant material (aerial parts; 500 g) was carried out as described earlier (Roeder and Wiedenfeld, 1977; Wiedenfeld and Roeder, 1979). Prep. TLC [silica gel F₂₅₄, CH₂Cl₂-MeOH-NH₄OH (25%), 75:24:1 v/v/v] yielded the alkaloids as oils (6 mg **1**, 5 mg of **2** and **3**, 8 mg **5** and **7**, 10 mg **4**, 1 mg **6**).

Canescine (**4**)

GC-MS *m/z* (%): [M]⁺ C₂₀H₃₃NO₇ 399 (0.41); C₁₉H₃₀NO₇ 384 (4.10); C₁₈H₂₈NO₆ 355 (0.82); C₁₈H₂₇NO₅ 338 (0.25); C₁₃H₂₀NO₄ 256 (9.84); C₁₃H₂₀NO₃ 238 (66.0); C₁₃H₁₈NO₂ 220 (21.4); C₁₀H₁₄NO₂ 180 (11.6); C₈H₁₀NO 136 (41.6); C₈H₁₀N 120 (100); C₆H₇N 93 (64.7); C₅H₆N 80 (20.1). ¹H NMR: δ (ppm): 5.83 (d, *J*_{2,3a} = 1.6 Hz, 1H, H-2), 5.38 (ddd, *J*_{7,8} = 1.9 Hz, *J*_{7,6} = 1.8; 1.6 Hz, 1H, H-7), 4.79 (dd, *J*_{9a,9b} = 13.9 Hz, *J*_{9a,8} = 9.1 Hz, 1H, H-9A), 4.67 (dd, *J*_{9b,9a} = 13.9 Hz, *J*_{9,8} = 6.2 Hz, 1H, H-9B), 4.35 (m, 1H, H-8), 4.07 (q, *J*_{13,14} = 6.4 Hz, 1H, H-13), 3.95 (ddd, *J*_{3a,3b} = 11.4 Hz, *J*_{3a,8} = 3.2 Hz, *J*_{3a,2} = 1.6 Hz, 1H, H-3A), 3.38 (dddd, *J*_{3b,3a} = 11.4, *J*_{3b,8} = 3.2, *J*_{3b,5a} = 2.0 Hz, *J*_{3b,2} = 1.6 Hz, 1H, H-3B), 3.33 (dm, *J*_{5a,5b} = 10.7, 1H, H-5A), 2.98 (3OH), 2.65 (ddd, *J*_{5b,5a} = 10.7, *J*_{5b,6} = 7.8, *J*_{5b,7} = 1.8 Hz, 1H, H-5B), 2.45 (s, 2H, H₂-20), 2.09 (dm, *J*_{6,5b} = 10.7, 2H, H₂-6), 2.00 (qq, *J*_{15,16/17} = 6.8 Hz, 1H, H-15), 1.26 (s, 6H, H₃-22/23), 1.19 (d, *J*_{14,13} = 6.4 Hz, 3H, H₃-14), 0.94 (d, *J*_{16,15} = 6.8 Hz, 3H, H₃-16), 0.91 (d, *J*_{17,15} = 6.8 Hz, 3H, H₃-17), ¹³C NMR: δ (ppm): 175.1 (C-11), 171.7 (C-19), 133.0 (C-1), 127.5 (C-2), 83.4 (C-12), 75.4 (C-8), 74.4 (C-7), 69.5 (C-13), 69.1 (C-21), 62.6 (C-3), 62.3 (C-9), 53.6 (C-5), 46.9 (C-20), 34.4 (C-6), 33.1 (C-15), 29.4 (C-22), 29.2 (C-23), 17.2 (C-14), 17.2 (C-16), 17.1 (C-17).

Canescenine (**6**)

GC-MS *m/z* (%): [M]⁺ C₂₀H₃₃NO₇ 399 (0.10); C₁₉H₃₀NO₇ 384 (1.56); C₁₈H₂₈NO₆ 355 (0.41);

C₁₈H₂₇NO₅ 338 (0.26); C₁₃H₂₀NO₄ 256 (9.59); C₁₃H₂₀NO₃ 238 (67.5); C₁₃H₁₈NO₂ 220 (20.6); C₁₀H₁₄NO₂ 180 (14.7); C₈H₁₀NO 136 (45.1); C₈H₁₀N 120 (100); C₆H₇N 93 (61.6); C₅H₆N 80 (20.2). ¹H NMR: δ (ppm): 4.74 (dd, *J*_{9a,9b} = 12.9 Hz, *J*_{9a,8} = 6.2 Hz, 1H, H-9A), 4.73 (dd, *J*_{9b,9a} = 12.9 Hz, *J*_{9,8} = 6.4 Hz, 1H, H-9B), 3.89 (q, *J*_{13,14} = 6.6 Hz, 1H, H-13), ¹³C NMR: δ (ppm): 71.1 (C-13), 16.0 (C-14), 17.8 (C-16), 14.2 (C-17). Further data are similar to **4**.

Acetylcanescine (**5**)

GC-MS *m/z* (%): [M]⁺ C₂₂H₃₅NO₈ 441 (0.73); C₂₁H₃₂NO₈ 426 (2.60); C₁₈H₂₈NO₆ 355 (2.36); C₁₃H₁₉NO₄ 255 (6.26); C₁₃H₂₀NO₃ 238 (62.4); C₁₃H₁₈NO₂ 220 (18.3); C₁₀H₁₄NO₂ 180 (38.9); C₈H₁₀NO 136 (47.2); C₈H₁₀N 120 (100); C₆H₇N 93 (73.9); C₅H₆N 80 (19.9). ¹H NMR: δ (ppm): 5.21 (q, *J*_{13,14} = 6.4 Hz, 1H, H-13), 2.00 (s, 3H, H₃-25), ¹³C NMR: δ (ppm): 170.4 (C-24), 72.4 (C-13), 21.2 (C-25). Further data are similar to **4**.

Acetylcanescenine (**7**)

GC-MS *m/z* (%): [M]⁺ C₂₂H₃₅NO₈ 441 (1.23); C₂₁H₃₂NO₈ 426 (2.38); C₂₀H₃₂NO₇ 398 (1.56); C₁₈H₂₈NO₆ 355 (1.39); C₁₃H₁₉NO₄ 255 (5.66); C₁₃H₂₀NO₃ 238 (58.2); C₁₃H₁₈NO₂ 220 (20.3); C₁₀H₁₄NO₂ 180 (44.3); C₈H₁₀NO 136 (43.4); C₈H₁₀N 120 (100); C₆H₇N 93 (80.3); C₅H₆N 80 (22.1). ¹H NMR: δ (ppm): 5.17 (q, *J*_{13,14} = 6.6 Hz, 1H, H-13), 2.03 (s, 3H, H₃-25), ¹³C NMR: δ (ppm): 170.4 (C-24), 73.7 (C-13), 21.3 (C-25). Further data are similar to **6**.

Acknowledgement

We are thankful to Dr. Branka Barl, Saskatchewan Herb Research Centre; Department of Horticulture Science, University of Saskatchewan, Saskatoon, Canada, for collecting and identifying the plant material.

Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln BAnz Nr. 111 vom 17.6.1992/Pharm. Ind. **54** (7), VII/177 (1992).
 Brauchli J., Lüthy J., Zweifel U., and Schlatter Ch. (1982), Pyrrolizidine alkaloids from *Symphytum officinale* L., and their percutaneous Absorption in rats. *Experientia* **38**, 1085–1087.
 Densmore F. (1928), Indian Use of Wild Plants for Crafts, Food, Medicine and Charms. Smithsonian Institution, Bureau of American Ethnology, United States Government Printing Office, Washington, p. 290.
 Jones A. J., Culvenor C. C. J., and Smith L. W. (1982), Pyrrolizidine alkaloids – a carbon-13 NMR study. *Aust. J. Chem.* **35**, 1173–1184.
 Kelley R. B., and Seiber J. N. (1992), Pyrrolizidine alkaloids from *Amsinckia*. *Phytochemistry* **31**, 2513–2518.
 Mohanraj S., and Herz W. (1982), High resolution proton NMR and carbon-13 NMR spectra of saturated pyrrolizidine monoester alkaloids. *J. Nat. Prod.* **45**, 328–336.
 Roeder E., and Wiedenfeld H. (1977), Isolation and structural elucidation of the alkaloid fuchsisenecionine from *Senecio fuchsii*. *Phytochemistry* **16**, 1462–1463.

Roeder E., Wiedenfeld H., and Stengl P. (1982), ¹³C-NMR-Daten der stereoisomeren Alkaloide aus *Symphytum officinale*. *Arch. Pharm (Weinheim)* **315**, 87–89.
 Roitman J. N. (1983), Pyrrolizidine alkaloids from *Amsinckia menziesii*. *Aust. J. Chem.* **36**, 769–778.
 Wiedenfeld H., and Roeder E. (1979), The pyrrolizidine alkaloid senecionine from *Senecio fuchsii*. *Phytochemistry* **18**, 1083–1084.
 Wiedenfeld H., and Roeder E. (1984), Pyrrolizidine alkaloids: structure and toxicity. *Dtsch. Apoth. Ztg.* **124**, 2116–2122.
 Wiedenfeld H., and Roeder E. (1991), Pyrrolizidine alkaloids from *Ageratum conyzoides*. *Planta Med.* **57**, 578–579.
 Wiedenfeld H., Pietrosiuk A., Furmanowa M., and Roeder E. (1998), Pigment compounds in *Lithospermum canescens* Lehm. Abstracts of Plenary Lectures, Short Lectures and Posters of the 46th Annual Congress Society for Medicinal Plant Research, University of Vienna, Vienna, Austria, p. G21.